sinopharm med. - SHTDY

SHTDY

Close Chg Chg %
13.58 -0.43 -3.17%

Pre-Market

13.15

-0.43 (3.17%)

Volume: 8.13K

Last Updated:

Nov 21, 2024, 3:50 PM EDT

Company Overview: sinopharm med. - SHTDY

SHTDY Key Data

Open

$13.11

Day Range

13.11 - 13.20

52 Week Range

10.13 - 16.31

Market Cap

$3.67B

Shares Outstanding

268.36M

Public Float

N/A

Beta

0.61

Rev. Per Employee

N/A

P/E Ratio

7.13

EPS

N/A

Yield

366.29%

Dividend

$0.50

EX-DIVIDEND DATE

Jun 18, 2024

SHORT INTEREST

N/A

AVERAGE VOLUME

21.07K

 

SHTDY Performance

1 Week
 
1.23%
 
1 Month
 
1.56%
 
3 Months
 
10.83%
 
1 Year
 
3.14%
 
5 Years
 
-22.19%
 

SHTDY Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings
Full Ratings ➔

About sinopharm med. - SHTDY

Sinopharm Group Co., Ltd. is a distributor of pharmaceutical and healthcare products and a value added supply chain service provider in the People's Republic of China. It operates through the following business segments: Pharmaceutical Distribution, Medical Devices, Retail Pharmacy, and Other Business. The Pharmaceutical Distribution segment provides distribution, logistics and other value-added services for domestic and international pharmaceutical and healthcare products manufacturers and other suppliers. The Medical Devices segment consists of the distribution of medical devices in China. The Retail Pharmacy segment refers to the network of retail drug stores in major cities of China via direct operations and franchises. The Other Business segment comprises of the production and sale of pharmaceutical products, chemical reagents and laboratory supplies. The company was founded on January 8, 2003 and is headquartered in Shanghai, China.

SHTDY At a Glance

Sinopharm Group Co., Ltd.
Sinopharm Group Building
Shanghai, Shanghai 200023
Phone 86-21-6321-1750 Revenue 84.20B
Industry Medical Distributors Net Income 1.28B
Sector Distribution Services 2023 Sales Growth 2.688%
Fiscal Year-end 12 / 2024 Employees 115,959
View SEC Filings

SHTDY Valuation

P/E Current 7.134
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 6.396
Price to Sales Ratio 0.097
Price to Book Ratio 0.334
Price to Cash Flow Ratio 4.242
Enterprise Value to EBITDA 5.361
Enterprise Value to Sales 0.235
Total Debt to Enterprise Value 0.794

SHTDY Efficiency

Revenue/Employee 726,131.077
Income Per Employee 11,020.033
Receivables Turnover 3.214
Total Asset Turnover 1.581

SHTDY Liquidity

Current Ratio 1.395
Quick Ratio 1.146
Cash Ratio 0.31

SHTDY Profitability

Gross Margin 7.83
Operating Margin 3.641
Pretax Margin 3.085
Net Margin 1.518
Return on Assets 2.399
Return on Equity 12.585
Return on Total Capital 4.871
Return on Invested Capital 10.267

SHTDY Capital Structure

Total Debt to Total Equity 149.448
Total Debt to Total Capital 59.911
Total Debt to Total Assets 29.072
Long-Term Debt to Equity 23.135
Long-Term Debt to Total Capital 9.275
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Sinopharm Med. - SHTDY

Collapse All in section
All values USD millions. 2020 2021 2022 2023 5-year trend
Sales/Revenue
66.13B 80.79B 82.00B 84.20B
Sales Growth
+7.44% +22.18% +1.49% +2.69%
Cost of Goods Sold (COGS) incl D&A
60.52B 74.22B 75.22B 77.61B
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
521.15M 608.13M 618.53M 625.30M
Depreciation
464.64M 548.95M 560.52M 566.59M
Amortization of Intangibles
56.51M 59.18M 58.02M 58.71M
COGS Growth
+7.45% +22.65% +1.34% +3.18%
Gross Income
5.61B 6.57B 6.78B 6.59B
Gross Income Growth
+7.30% +17.10% +3.24% -2.76%
Gross Profit Margin
+8.48% +8.13% +8.27% +7.83%
2020 2021 2022 2023 5-year trend
SG&A Expense
2.94B 3.42B 3.50B 3.53B
Research & Development
- - - -
-
Other SG&A
2.94B 3.42B 3.50B 3.53B
SGA Growth
+10.13% +16.20% +2.26% +0.83%
Other Operating Expense
- 11.04M (1.96M) 26.86M
Unusual Expense
38.83M 81.71M 3.22M (14.27M)
EBIT after Unusual Expense
2.61B 3.07B 3.25B 3.08B
Non Operating Income/Expense
26.97M 18.11M (99.06M) (34.29M)
Non-Operating Interest Income
97.99M 86.61M 80.60M 104.92M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
524.55M 614.24M 554.34M 447.95M
Interest Expense Growth
-0.52% +17.10% -9.75% -19.19%
Gross Interest Expense
525.03M 616.65M 557.54M 450.78M
Interest Capitalized
485.78K 2.41M 3.20M 2.83M
Pretax Income
2.12B 2.47B 2.60B 2.60B
Pretax Income Growth
+13.63% +16.71% +5.18% -0.03%
Pretax Margin
+3.20% +3.06% +3.17% +3.09%
Income Tax
507.20M 610.66M 626.46M 635.47M
Income Tax - Current - Domestic
538.33M 657.00M 665.28M 656.39M
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
(31.13M) (46.33M) (38.83M) (20.92M)
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - (10.72K)
-
Consolidated Net Income
1.75B 2.03B 2.13B 2.12B
Minority Interest Expense
711.37M 822.74M 864.28M 840.66M
Net Income
1.04B 1.20B 1.27B 1.28B
Net Income Growth
+15.10% +15.53% +5.25% +0.93%
Net Margin Growth
+1.57% +1.49% +1.54% +1.52%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
1.04B 1.20B 1.27B 1.28B
Preferred Dividends
- - - -
-
Net Income Available to Common
1.04B 1.20B 1.27B 1.28B
EPS (Basic)
1.6735 1.9275 2.0286 2.0474
EPS (Basic) Growth
+9.87% +15.18% +5.25% +0.93%
Basic Shares Outstanding
622.23M 624.13M 624.13M 624.13M
EPS (Diluted)
1.6734 1.9275 2.0286 2.0474
EPS (Diluted) Growth
+9.93% +15.18% +5.25% +0.93%
Diluted Shares Outstanding
622.26M 624.13M 624.13M 624.13M
EBITDA
3.17B 3.76B 3.87B 3.69B
EBITDA Growth
+5.66% +18.34% +3.12% -4.71%
EBITDA Margin
+4.80% +4.65% +4.72% +4.38%

Sinopharm Med. in the News